Diagens Annual Results: 100B-Parameter Model Reshapes Medical AI Landscape; Licensing Revenue Becomes Primary Growth Engine

B HONG KONG and HANGZHOU, China, April 30, 2026 /PRNewswire/ — Hangzhou Diagens Biotech Co., Ltd. (HKEX: 2526, “Diagens”), a pioneer in medical imaging foundation…
posteditor
posteditor
Articles: 17424

Other News